Altered thalamic membrane phospholipids in schizophrenia: A postmortem study

Biological Psychiatry

Volumn 56, Issue 1, 2004, Pages 41-45

  Schmitt, Andrea ^a   Wilczek, Katrin ^a   Blennow, Kaj ^b   Maras, Athanasios ^a   Jatzko, Alexander ^a   Petroianu, Georg ^c   Braus, Dieter F ^a   Gattaz, Wagner F ^d  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

membrane lipids; phospholipids; postmortem; schizophrenia; Thalamus; thin layer chromatography

Indexed keywords

GALACTOSYLCERAMIDE; LYSOPHOSPHATIDYLCHOLINE; MEMBRANE PHOSPHOLIPID; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLGLYCEROL; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLSERINE; SPHINGOMYELIN; SULFATIDE;

ADULT; AGED; ARTICLE; AUTOPSY; CONTROLLED STUDY; CORRELATION ANALYSIS; EXTRACTION; FEMALE; HOMOGENATE; HUMAN; HUMAN TISSUE; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SCHIZOPHRENIA; THALAMUS; THIN LAYER CHROMATOGRAPHY;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; AUTOPSY; CASE-CONTROL STUDIES; FEMALE; GALACTOSYLCERAMIDES; HUMANS; MALE; MEMBRANE LIPIDS; MIDDLE AGED; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLSERINES; SCHIZOPHRENIA; SPHINGOMYELINS; SULFOGLYCOSPHINGOLIPIDS; THALAMUS;

EID: 3042522884     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2004.03.019     Document Type: Article

References (44)

1. Adolfsson R., Gottfries C.G., Nystrom L., Winblad B. Prevalence of dementia disorders in institutionalized Swedish old people. The work load imposed by caring for these patients. Acta Psychiatr Scand. 63:1981;225-244
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Third Revised Edition (DSM-III-R). 1987;American Psychiatric Association, Washington, DC
3. Ananth H., Popescu I., Critchley H.D., Good C.D., Frackowiak R.S., Dolan R.J. Cortical and subcortical gray matter abnormalities in schizophrenia determined through structural magnetic resonance imaging with optimized volumetric voxel-based morphometry. Am J Psychiatry. 159:2002;1497-1505
4. Andreasen N.C., Arndt S., Swayze V. 2nd, Cizadlo T., Flaum M., O'Leary D., et al. Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. Science. 266:1994;294-298
5. Andreasen N.C., Nopoulos P., O'Leary D.S., Miller D.D., Wassink T., Flaum M. Defining the phenotype of schizophrenia Cognitive dysmetria and its neural mechanisms. Biol Psychiatry. 46:1999;908-920
6. Bartzokis G. Age-related myelin breakdown A developmental model of cognitive decline and Alzheimer's disease. Neurobiol Aging. 25:2004;5-18
7. Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 37:1959;911-917
8. Braus D.F., Weber-Fahr W., Tost H., Ruf M., Henn F.A. Sensory information processing in neuroleptic-naive first-episode schizophrenic patients A functional magnetic resonance imaging study. Arch Gen Psychiatry. 59:2002;696-701
9. Byne W., Buchsbaum M.S., Kemether E., Hazlett E.A., Shinwari A., Mitropoulou V., et al. Magnetic resonance imaging of the thalamic mediodorsal nucleus and pulvinar in schizophrenia and schizotypal personality disorder. Arch Gen Psychiatry. 58:2001;133-140
10. Byne W., Buchsbaum M.S., Mattiace L.A., Hazlett E.A., Kemether E., Elhakem S.L., et al. Postmortem assessment of thalamic nuclear volumes in subjects with schizophrenia. Am J Psychiatry. 159:2002;59-65
11. Chang G.H., Barbaro N.M., Pieper R.O. Phosphatidylserine-dependent phagocytosis of apoptotic glioma cells by normal human microglia, astrocytes, and glioma cells. Neuro-oncol. 2:2000;174-183
12. Danos P., Baumann B., Bernstein H.G., Stauch R., Krell D., Falkai P., et al. The ventral lateral posterior nucleus of the thalamus in schizophrenia A post-mortem study. Psychiatry Res. 114:2002;1-9
13. Davis K.L., Stewart D.G., Friedman J.I., Buchsbaum M., Harvey P.D., Hof P.R., et al. White matter changes in schizophrenia Evidence for myelin-related dysfunction. Arch Gen Psychiatry. 60:2003;443-456
14. Deicken R.F., Eliaz Y., Chosiad L., Feiwell R., Rogers L. Magnetic resonance imaging of the thalamus in male patients with schizophrenia. Schizophr Res. 58:2002;135-144
15. Ende G., Braus D.F., Walter S., Henn F.A. Lower concentration of thalamic n-acetylaspartate in patients with schizophrenia A replication study. Am J Psychiatry. 158:2001;1314-1316
16. Fukuzako H., Fukuzako T., Hashiguchi T., Kodama S., Takigawa M., Fujimoto T. Changes in levels of phosphorus metabolites in temporal lobes of drug-naive schizophrenic patients. Am J Psychiatry. 156:1999;1205-1208
17. Gattaz W.F., Schmitt A., Maras A. Increased platelet phospholipase A2 activity in schizophrenia. Schizophr Res. 16:1995;1-6
18. Hakak Y., Walker J.R., Li C., Wong W.H., Davis K.L., Buxbaum J.D., et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A. 98:2001;4746-4751
19. Hannun Y.A. The sphingomyelin cycle and the second messenger function of ceramide. J Biol Chem. 269:1994;3125-3128
20. Hof P.R., Haroutunian V., Friedrich V.L. Jr, Byne W., Buitron C., Perl D.P., et al. Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol Psychiatry. 53:2003;1075-1085
21. Hulshoff Pol H.E., Schnack H.G., Mandl R.C., van Haren N.E., Koning H., Collins D.L., et al. Focal gray matter density changes in schizophrenia. Arch Gen Psychiatry. 58:2001;1118-1125
22. Jensen J.E., Al-Semaan Y.M., Williamson P.C., Neufeld R.W., Menon R.S., Schaeffer B., et al. Region-specific changes in phospholipid metabolism in chronic, medicated schizophrenia (31)P-MRS study at 4.0 Tesla. Br J Psychiatry. 180:2002;39-44
23. Jones E. The Thalamus. 1985;Plenum Publishing, New York
24. Kemether E.M., Buchsbaum M.S., Byne W., Hazlett E.A., Haznedar M., Brickman A.M., et al. Magnetic resonance imaging of mediodorsal, pulvinar, and centromedian nuclei of the thalamus in patients with schizophrenia. Arch Gen Psychiatry. 60:2003;983-991
25. Kraus R., Wuthe J., Rufer R. Method for determination of different phospholipids by circular high-performance thin-layer chromatography. J Chromatogr. 413:1987;257-263
26. Lejoyeux M., Maziere J.C., Mora L., Auclair M., Maziere C. Sphingomyelinase fibroblast activity and psychoactive drugs. Biol Psychiatry. 30:1991;841-843
27. Lewis D.A., Cruz D.A., Melchitzky D.S., Pierri J.N. Lamina-specific deficits in parvalbumin-immunoreactive varicosities in the prefrontal cortex of subjects with schizophrenia Evidence for fewer projections from the thalamus. Am J Psychiatry. 158:2001;1411-1422
28. Marion J., Wolfe L.S. Origin of the arachidonic acid released post-mortem in rat forebrain. Biochim Biophys Acta. 574:1979;25-32
29. Menon V., Anagnoson R.T., Glover G.H., Pfefferbaum A. Functional magnetic resonance imaging evidence for disrupted basal ganglia function in schizophrenia. Am J Psychiatry. 158:2001;646-649
30. Omori M., Murata T., Kimura H., Koshimoto Y., Kado H., Ishimori Y., et al. Thalamic abnormalities in patients with schizophrenia revealed by proton magnetic resonance spectroscopy. Psychiatry Res. 98:2000;155-162
31. Pakkenberg B. Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics. Arch Gen Psychiatry. 47:1990;1023-1028
32. Pettegrew J.W., Keshavan M.S., Panchalingam K., Strychor S., Kaplan D.B., Tretta M.G., et al. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch Gen Psychiatry. 48:1991;563-568
33. Ray J.P., Price J.L. The organization of projections from the mediodorsal nucleus of the thalamus to orbital and medial prefrontal cortex in macaque monkeys. J Comp Neurol. 337:1993;1-31
34. 2 activities in brain of patients with schizophrenia. Brain Res. 821:1999;407-413
35. Sandell J.H., Peters A. Disrupted myelin and axon loss in the anterior commissure of the aged rhesus monkey. J Comp Neurol. 466:2003;14-30
36. Sastry P.S. Lipids of nervous tissue Composition and metabolism. Prog Lipid Res. 24:1985;69-176
37. Sawai H., Hannun Y.A. Ceramide and sphingomyelinases in the regulation of stress responses. Chem Phys Lipids. 102:1999;141-147
38. Schmitt A., Maras A., Petroianu G., Braus D.F., Scheuer L., Gattaz W.F. Effects of antipsychotic treatment on membrane phospholipid metabolism in schizophrenia. J Neural Transm. 108:2001;1081-1091
39. Stanley J.A., Williamson P.C., Drost D.J., Carr T.J., Rylett R.J., Malla A., et al. An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. Arch Gen Psychiatry. 52:1995;399-406
40. Tavares H., Yacubian J., Talib L.L., Barbosa N.R., Gattaz W.F. Increased phospholipase A2 activity in schizophrenia with absent response to niacin. Schizophr Res. 61:2003;1-6
41. Touchstone J.C., Chen J.C., Beaver K.M. Improved separation of phospholipids in thin-layer chromatography. Lipids. 15:1980;61-62
42. Trzeciak H.I., Kalacinski W., Malecki A., Kokot D. Effect of neuroleptics on phospholipase A2 activity in the brain of rats. Eur Arch Psychiatry Clin Neurosci. 245:1995;179-182
43. Vos J.P., de Haas C.G., van Golde L.M., Lopes-Cardozo M. Relationships between phosphatidylcholine, phosphatidylethanolamine, and sphingomyelin metabolism in cultured oligodendrocytes. J Neurochem. 68:1997;1252-1260
44. Yao J.K., Leonard S., Reddy R.D. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr Res. 42:2000;7-17